AIG scored an exit as genetic disease and cancer drug developer BridgeBio Pharma floated above its range while increasing the number of shares in its IPO.
Elaine Jones, vice-president at pharmaceutical company Pfizer’s corporate venture capital unit, has shared highlights of her career with GCV ahead of her departure in April.
Having emerged from the Merck Serono Entrepreneur Partnership Program (EPP) in 2015, Prexton Therapeutics raised a total $41m of funding before it was acquired by pharmaceutical firm Lundbeck for an estimated $1.1bn last year.
In the second half of our guide to corporate venturing's biggest trends in 2018, we look at the growth of Chinese tech companies, genomics, advances in transport tech and the growth of the scooter rental space.
SoftBank Vision Fund led a series B round for the cancer therapy developer that was also backed by GV and Alexandria Venture Investments.
The molecular product technology provider followed a nine-figure, SoftBank-led round two years ago with a series C led by the corporate's Vision Fund.
Merck & Co, AstraZeneca and Alexion are all in line for exits after Moderna Therapeutics, valued at $7.5bn earlier this year, filed for its initial public offering.
GSK, Sphera Global and Medison-backed gene therapy developer Orchard Therapeutics raised $200m in an offering that could possibly close at $230m.